Pieris Receives Third Milestone Payment in Daiichi Sankyo Collaboration to
Develop Anticalin® Therapeutics
FREISING, Germany -- November 12, 2013
Pieris AG has achieved its third milestone overall in its discovery and
development collaboration with Daiichi Sankyo Company Limited (hereinafter
Daiichi Sankyo; headquartered in Chuo Ward, Tokyo, TSE 4568), triggering an
undisclosed payment, the company announced today. The milestone, which is the
first for the companies’ second collaborative program, was triggered by the
delivery of several functional picomolar affinity Anticalins^® specific for an
undisclosed Daiichi Sankyo target.
“This achievement demonstrates not only the repeated success we continue to
experience in our relationship with Daiichi Sankyo, but also the ability of
the Anticalin technology to deliver highly potent binders against a very
diverse spectrum of targets,” Stephen Yoder, CEO of Pieris stated. “Once
again, Pieris has rapidly delivered these compounds, and subsequent milestones
for each program are well within our sights.”
Under the terms of the 2011 agreement, Pieris receives committed research
funding and payments for the achievement of research, preclinical, regulatory
and commercial milestones. The partnership could encompass for Pieris more
than € 100 million per program in license fees, funding and milestones, not
including royalties on sales from marketed Anticalin proteins resulting from
the collaboration. Daiichi Sankyo will have exclusive marketing rights
worldwide for all such products.
Anticalins are therapeutic proteins derived from human lipocalins, rationally
engineered to solve for the pharmacological and pharmaceutical limitations of
both protein- and non-protein-based drug platforms.
About Daiichi Sankyo
The Daiichi Sankyo Group is dedicated to the creation and supply of innovative
pharmaceutical products to address the diversified, unmet medical needs of
patients in both mature and emerging markets. While maintaining its portfolio
of marketed pharmaceuticals for hypertension, hyperlipidemia, and bacterial
infections, the Group is engaged in the development of treatments for
thrombotic disorders and focused on the discovery of novel oncology and
cardiovascular-metabolic therapies. Furthermore, the Daiichi Sankyo Group has
created a "Hybrid Business Model," which will respond to market and customer
diversity and optimise growth opportunities across the value chain. For more
information, please visit: www.daiichisankyo.com.
Pieris AG is an independent, clinical-stage biotechnology company advancing
its proprietary Anticalin^® technology to create differentiated drugs that are
safer and more effective than conventional approaches. Exclusive to Pieris,
Anticalins promise to address high-unmet medical needs and expand the
potential of targeted therapeutics. The company currently has a diverse
proprietary pipeline and has ongoing R&D collaborations with Daiichi Sankyo,
the Sanofi Group, Zydus Cadila and Allergan. Privately held, Pieris has been
funded by premier biotechnology-focused venture capital, including lead
investors OrbiMed Advisors and Global Life Science Ventures. For more
information, please visit: www.pieris-ag.com.
Anticalin^®, Anticalins^® are registered trademarks of Pieris AG.
For more information, please contact:
Stephen Yoder, CEO
+49 (0) 8161 1411 400
+49 172 861 8540
Additional information is available at www.pieris-ag.com.
Press spacebar to pause and continue. Press esc to stop.